Compare THRM & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRM | DSGN |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 844.7M | 819.6M |
| IPO Year | 1996 | 2021 |
| Metric | THRM | DSGN |
|---|---|---|
| Price | $30.23 | $13.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $37.20 | $15.25 |
| AVG Volume (30 Days) | 228.0K | ★ 469.9K |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $554,979,000.00 | N/A |
| Revenue This Year | $4.96 | N/A |
| Revenue Next Year | $7.12 | N/A |
| P/E Ratio | $215.00 | ★ N/A |
| Revenue Growth | ★ 50.16 | N/A |
| 52 Week Low | $25.47 | $3.11 |
| 52 Week High | $39.48 | $17.25 |
| Indicator | THRM | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.68 | 55.22 |
| Support Level | $27.38 | $9.71 |
| Resistance Level | $32.25 | $13.54 |
| Average True Range (ATR) | 1.10 | 1.07 |
| MACD | 0.17 | 0.02 |
| Stochastic Oscillator | 51.11 | 25.42 |
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the USA, China, South Korea, Germany, Japan, the Czech Republic, and other countries.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.